Daily Cardiology Research Analysis
Three studies stand out in cardiology: a mechanistic AI approach (LogiRx) identified escitalopram as an off-target inhibitor of cardiomyocyte hypertrophy with in vitro, in vivo, and human data support; a basic-translational study showed tirzepatide protects against doxorubicin cardiotoxicity via HRD1–Nrf2 signaling; and a large population cohort linked diabetes and elevated glucose to aortic/mitral valve calcification and aortic stenosis with mediation by triglycerides, hypertension, and BMI.
Summary
Three studies stand out in cardiology: a mechanistic AI approach (LogiRx) identified escitalopram as an off-target inhibitor of cardiomyocyte hypertrophy with in vitro, in vivo, and human data support; a basic-translational study showed tirzepatide protects against doxorubicin cardiotoxicity via HRD1–Nrf2 signaling; and a large population cohort linked diabetes and elevated glucose to aortic/mitral valve calcification and aortic stenosis with mediation by triglycerides, hypertension, and BMI.
Research Themes
- AI-driven mechanistic discovery and drug repurposing in cardiac remodeling
- Metabolic drivers of valvular calcification and stenosis
- Cardio-oncology: GLP-1/GIP agonists mitigating chemotherapy cardiotoxicity
Selected Articles
1. Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy.
The authors introduce LogiRx, a mechanistic AI approach that predicts drug-induced signaling pathways. They demonstrate that escitalopram attenuates cardiomyocyte hypertrophy via an off-target serotonin receptor/PI3Kγ pathway, validating predictions in neonatal cardiomyocytes, adult mice, and human databases.
Impact: This work couples explainable AI with experimental validation to uncover an actionable off-target mechanism, enabling drug repurposing to limit cardiac remodeling. It bridges computational predictions with translational evidence across species.
Clinical Implications: Escitalopram may reduce cardiac hypertrophy risk in certain populations, suggesting a potential adjunctive strategy to limit remodeling. Mechanistic targets (serotonin receptor/PI3Kγ) offer opportunities for precision therapy development.
Key Findings
- Developed LogiRx, a logic-based mechanistic ML framework predicting drug-induced pathways.
- Predicted and validated that escitalopram inhibits cardiomyocyte hypertrophy via a serotonin receptor/PI3Kγ pathway.
- Escitalopram reduced hypertrophy in cultured cardiomyocytes and in a mouse hypertrophy/fibrosis model.
- Database analyses showed lower incidence of cardiac hypertrophy in patients on escitalopram compared with SSRIs not targeting the serotonin receptor.
Methodological Strengths
- Multi-system validation (in vitro neonatal cardiomyocytes, in vivo adult mouse model, and human databases).
- Mechanistic, explainable AI framework providing testable pathway hypotheses.
Limitations
- Not a randomized clinical trial; human evidence is observational.
- Off-target mechanism and dose-response for clinical translation require prospective trials.
Future Directions: Prospective, randomized studies to test escitalopram’s antihypertrophic effect and target engagement; exploration of PI3Kγ modulation and serotonin receptor selectivity for precision therapeutics.
Cardiomyocyte hypertrophy is a key clinical predictor of heart failure. High-throughput and AI-driven screens have the potential to identify drugs and downstream pathways that modulate cardiomyocyte hypertrophy. Here, we developed LogiRx, a logic-based mechanistic machine learning method that predicts drug-induced pathways. We applied LogiRx to discover how drugs discovered in a previous compound screen attenuate cardiomyocyte hypertrophy. We experimentally validated LogiRx predictions in neonatal cardiomyocytes, adult mice, and two patient databases. Using LogiRx, we predi
2. Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
In mouse and cardiomyoblast models, tirzepatide mitigated doxorubicin cardiotoxicity by reducing oxidative stress and apoptosis. Mechanistically, tirzepatide inhibited ER stress–induced HRD1 upregulation, preventing Nrf2 ubiquitination and degradation, thereby enhancing Nrf2 activity.
Impact: Identifies a druggable ER stress–HRD1–Nrf2 axis for chemotherapy cardioprotection using a clinically available GIP/GLP-1 agonist. Bridges metabolic therapeutics and cardio-oncology with a clear mechanistic pathway.
Clinical Implications: Supports evaluation of tirzepatide (or Nrf2-preserving strategies) as cardioprotective adjuncts during anthracycline therapy, especially for high-risk patients. Encourages biomarker-driven trials targeting ER stress/HRD1–Nrf2 signaling.
Key Findings
- Tirzepatide protected mice from doxorubicin-induced myocardial injury, dysfunction, and death.
- In H9c2 cells, tirzepatide attenuated doxorubicin-induced oxidative damage and apoptosis.
- Mechanism: tirzepatide prevented ER stress–induced HRD1 upregulation, reduced Nrf2 ubiquitination and degradation, and enhanced Nrf2 nuclear translocation and transcriptional activity.
Methodological Strengths
- Integrated in vivo (murine) and in vitro (H9c2) experiments with echocardiography, histology, and RNA-seq.
- Mechanistic perturbations using Ad-Hrd1 and siNrf2 to confirm pathway dependency.
Limitations
- Preclinical models; clinical efficacy and dosing in humans are unknown.
- H9c2 cell line may not fully recapitulate adult human cardiomyocytes.
Future Directions: Pilot clinical trials testing tirzepatide as a cardioprotective adjunct in anthracycline regimens; validation of HRD1–Nrf2 biomarkers for patient selection and response monitoring.
AIMS: Doxorubicin (DOX), an effective and commonly used chemotherapeutic agent, often triggers dosage-dependent and potentially lethal cardiotoxicity, which heavily limits its clinical application in cancer survivors. However, no actual pharmacological therapeutics for this adverse effect are available. Tirzepatide (TZP), a novel GIP/GLP-1 receptor agonist, exhibits efficacy in controlling glycaemia and has very recently been approved for the treatment of type 2 diabetes. Several clinical trials provided evidence that TZP treatment contributed to a substantial reduction in HbA1c levels, body weight, and cardiovascular risk factors through the involvement of biochemical and molecular mechanisms that needed to be deeply explored. Here, we aimed to investigate the role of TZP in DOX-induced cardiotoxicity and to clarify the underlying mechanisms. METHODS AND RESULTS: Male C57BL/6 mice were exposed to subcutaneous injections of TZP or an equal volume of vehicle once a day for 14 consecutive days. To generate DOX-induced cardiotoxicity, the mice received a single intraperitoneal injection of DOX (15 mg/kg). In vitro studies were performed on the H9c2 cell line in exposure to DOX alone or combined with TZP incubation. Echocardiographic measurement, histological assessment, and molecular analysis were obtained to determine the impact of TZP treatment on cardiotoxicity induced by DOX insult. To explore the underlying mechanisms, we performed RNA sequencing of murine heart tissue to screen for the potential targets. Moreover, Ad-Hrd1 and siNrf2 were utilized to further confirm the involvement of HRD1 and Nrf2 in this process. Mice with TZP administration were protected from myocardial injury, cardiac dysfunction, and fatality in response to DOX. A significant reduction in both oxidative stress and cardiomyocyte apoptosis induced by DOX injection was also observed in the presence of TZP. Consistently, results obtained from in vitro studies revealed that DOX challenge impaired cell viability and led to elevated oxidative damage and cellular apoptosis, which were significantly alleviated in TZP-treated H9c2 cells. Mechanistically, we provided direct evidence that the cardioprotective effect of TZP was mediated by the transcription factor Nrf2 in an HRD1-dependent manner. Upon DOX treatment, TZP incubation could prevent ER stress-induced HRD1 upregulation in cardiomyocytes and subsequently decrease the ubiquitylation and degradation of Nrf2, thus enhancing its protein expression level, nuclear translocation, and transcription activity, ultimately contributing to the decreased oxidative stress and cardiomyocyte apoptosis.
3. Diabetes and elevated plasma glucose in heart valve calcification and disease: the Copenhagen General Population Study.
In over 110,000 individuals, diabetes and elevated plasma glucose were associated with higher risks of aortic and mitral valve calcification and aortic valve stenosis. Mediation analyses showed that hypertension (≈19%) and BMI (≈27%), and to a lesser extent triglycerides, explained part of the diabetes–aortic stenosis association.
Impact: Links metabolic dysregulation to valvular calcification and stenosis at population scale, quantifying modifiable mediators and informing preventive strategies beyond lipid lowering.
Clinical Implications: Aggressive management of hypertension, weight, and triglycerides in diabetes may mitigate future valvular calcification and aortic stenosis risk. Supports incorporating glycemic status into valvular disease risk stratification.
Key Findings
- Diabetes was associated with aortic (OR 1.67) and mitral (OR 1.89) valve calcification; and with incident aortic valve stenosis (HR 1.71).
- Elevated glucose (≥6.6 mmol/L) vs. ≤5.1 mmol/L was associated with higher odds of aortic (OR 1.27) and mitral (OR 1.44) calcification and with aortic stenosis (HR 1.33).
- Mediation: in diabetes–aortic stenosis, 27% of the association was explained by BMI, 19% by hypertension, and 4.8% by triglycerides.
Methodological Strengths
- Very large population cohort (N=110,291) with health registry outcomes and CT sub-cohort (N=12,006).
- Mediation analysis quantifying contributions of triglycerides, hypertension, and BMI.
Limitations
- Observational design; residual confounding cannot be excluded.
- CT subset may introduce selection bias; causality not established.
Future Directions: Interventional studies targeting hypertension, adiposity, and triglycerides in diabetes to test whether valvular calcification/stenosis progression can be attenuated.
AIMS: The only treatment available for aortic valve stenosis is valve replacement, which makes it important to identify modifiable risk factors. We tested the hypotheses that diabetes and elevated plasma glucose are associated with aortic and mitral valve calcification and aortic valve stenosis, and that these associations are explained partly by elevated plasma triglycerides, hypertension, and body mass index (BMI). METHODS AND RESULTS: In the Copenhagen General Population Study with 110 291 individuals, we evaluated risk of aortic valve stenosis and mitral valve regurgitation from health registers, and in a subset of 12 006 cardiac CT scanned individuals aortic and mitral valve calcification. Of individuals with cardiac CT, 3018 (25%) had aortic and 1521 (13%) had mitral valve calcification. For individuals with cardiac CT, 3018 (25%) had aortic and 1521 (13%) had mitral valve calcification. For individuals with diabetes, the multi-variable adjusted odds ratios were 1.67 (95%:1.34-2.08) for aortic and 1.89 (1.48-2.40) for mitral valve calcification. The corresponding hazard ratio was 1.71 (1.44-2.03) for aortic valve stenosis.For individuals with glucose ≥6.6 mmol/L (≥118 mg/dL) vs. ≤5.1 mmol/L (≤92 mg/dL), the multi-variable adjusted odds ratios were 1.27 (1.07-1.52) for aortic and 1.44 (1.18-1.77) for mitral valve calcification. The corresponding hazard ratio was 1.33 (1.12-1.57) for aortic valve stenosis.In the relationship between diabetes and aortic valve stenosis, 4.8% (95% CI: 0.5-11%) of the association was explained by plasma triglycerides, 19% (14-28%) by hypertension, and 27% (18-43%) by BMI.